Trial Profile
An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima in Patients With Rheumatoid Arthritis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Anti-TNF monoclonal antibodies
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Celltrion
- 09 Feb 2024 Status changed from recruiting to discontinued.
- 12 Jul 2021 Results of a pooled analysis assessing long-term safety and effectiveness over 5 years from three observational studies: NCT02557295, NCT02326155 and NCT02557308 published in the Advances in Therapy
- 30 Apr 2020 Results of post marketing pooled analysis of six observational studies published in the BioDrugs